SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results triggered a sharp selloff as earnings and advertising-related results missed expectations, while heavy AI infrastructure spending drove negative free cash flow and raised concerns about returns. Traders are divided: some see the reaction as excessive given strong Google Cloud growth and are buying the dip, while others worry that rising capex and slowing search growth will pressure cash generation.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings and revenue miss, alongside concerns about rising AI capital spending and cash burn, is driving the discussion. Traders are divided between viewing strong Google Cloud growth as evidence the investment is paying off and worrying that spending, slower search growth, and pressure on cash flow outweigh it.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows quarterly report sparked a sharp selloff despite solid revenue growth and a raised full-year outlook, as an earnings miss and slower-than-expected forward contracted-revenue growth raised concerns about decelerating momentum and a valuation priced for stronger results. Traders are split between calling the reaction an overreactionpointing to the companys AI opportunity and strong underlying growthand viewing the outlook as a reason for further caution.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts fiscal first-quarter results beat expectations, with accelerating Azure growth and lower-than-expected capital spending prompting an initial bullish reaction. Traders remain divided over whether cloud momentum and spending discipline outweigh concerns about AI investment returns and cash flow, while some noted the post-earnings gains faded.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Speculation that Marvell is in advanced talks to acquire Lumentum (LITE) is driving discussion, with traders weighing potential AI-optics and data-center synergies against concerns about the deals cost, dilution and financing. The report is treated as unconfirmed, and reactions include both support for the strategic fit and concern that it could pressure MRVL shares.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings Q3 results and conference-call comments have put cash use, future dilution, commercialization timing, and the companys strategy for VK2735 under scrutiny. Traders disagree over whether management is leaning toward going it alone or may partner or sell; frustration about the share-price decline contrasts with optimism about the obesity-drug pipeline and its maintenance data.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles investor-day outlook for strong long-term growth, a return to positive free cash flow, and capped additional financing eased concerns about AI infrastructure spending and debt, driving a sharp rally. Bulls welcomed the added clarity, while skeptics questioned whether the projections are achievable and pointed to the stocks pullback after its surge.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports that Marvell is in advanced talks to acquire Lumentum sparked the sharp move, with traders debating whether a deal is real and questioning how Marvell would finance it. The takeover remains unconfirmed, and some traders dismiss the report as false speculation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Attention centers on POETs scheduled Q3 report and whether optical-engine sampling and the Lumilens partnership will translate into confirmed production shipments and customer orders. Bulls see an AI-datacenter photonics opportunity, while skeptics point to limited disclosed revenue, uncertainty about the partnerships status, and frustration with managements sparse updates.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets quarterly results beat estimates and its full-year outlook was raised, but traders focused on slowing product and billings growth and a weaker service outlook, driving a steep post-earnings selloff. The reaction is split between investors calling the drop an overreaction and buying the dip, and those pointing to valuation and growth concerns as reasons for further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edition of the companys rural health report, The State of Rural Hospitals and Cardiovascular Care, aimed at helping rural healthcare leaders, policymakers...

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa. The new facility gives Cardio Diagnostics end-to-end control over the...

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (Cardio Diagnostics or the Company), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor...

Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more […]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells […]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection

Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume.&#160;Cardio Diagnostics Holdings (NASDAQ: CDIO)&#160;reports&#160;that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional [&#8230;]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests [&#8230;]

Atlas Healthcare Physicians to Cover Cardio Diagnostics Precision Cardiovascular Medicine Tests Across Its Network

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics tests, Epi+Gen CHD and...

Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI

Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the&#160;American Heart Association (“AHA”), cardiovascular disease&#160;accounted&#160;for more than 940,000 deaths in the United States in 2022, maintaining its position as the [&#8230;]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ:&#160;CDIO)&#160;is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a [&#8230;]

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated comorbidities, including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded by Meeshanthini V. Dogan and Robert Philibert in 2017 and is headquartered in Chicago, IL.

Cardio Diagnostics Holdings Inc

Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

Equity

Neutral Sentiment

Biotech stocks, particularly in the small- and mid-cap space, were hot topics among retail investors in 2024, often spurred by major announcements or clinical developments.&nbsp;Collectively, these stocks attracted significant chatter on Stocktwits.&nbsp;Here are the top five biotech stocks with the highest message volume growth this year:Tonix Pharmaceuticals Holding Corp. (TNXP): +47,066% Message VolumeTonix focuses on developing therapies to treat and prevent diseases. Its TNX-102 SL, a non-opioid analgesic for fibromyalgia, gained attention when the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">accepted</a> its New Drug Application in December. Earlier in the year, the company also reiterated its&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">commitment</a> to developing an mpox vaccine. Despite these milestones, TNXP shares are down over 97% this year.Candel Therapeutics Inc. (CADL): +16,000% Message VolumeCandel develops viral immunotherapies targeting cancer. Its lead product, CAN-2409, is under trial for various cancers, including prostate and non-small cell lung cancer. Positive late-stage&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">results</a> released this month for CAN-2409 in prostate cancer drove retail interest. Shares of CADL are up over 500% this year.Cardio Diagnostics Holdings Inc. (CDIO): +11,650% Message VolumeCardio Diagnostics gained traction with its AI-powered PrecisionCHD test for coronary heart disease. The test demonstrated significant cost-saving potential in healthcare, according to the company. Cardio also received final pricing determinations from the Centers for Medicare &amp; Medicaid Services for its products. Its stock has fallen nearly 63% year-to-date.Recursion Pharmaceuticals Inc. (RXRX): +9,600% Message VolumeRecursion uses AI and automation to discover medicines. A $50 million investment from Nvidia to support AI-driven drug discovery efforts primarily sparked significant retail interest this year, although RXRX shares have declined 22% so far in 2024.Galectin Therapeutics Inc. (GALT): +5,800% Message VolumeGalectin’s focus on fibrotic and inflammatory diseases, led by its drug belapectin, caught investors’ attention despite mixed trial results. While the drug didn’t meet statistical significance for a key endpoint in an early liver disease trial, further data analysis is expected in early 2025. GALT shares are down over 48% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

Candel Therapeutics Inc

Galectin Therapeutics Inc

Recursion Pharmaceuticals Inc

Tonix Pharmaceuticals Holding Corp

Yes, the bottom is in

No, more downside ahead

Too early to tell

Depends on the stock

Neocloud stocks like $NBIS, $CRWV, $IREN, and $APLD are rebounding after a brutal October. Have they bottomed?

Stocktwits

Nebius Group N.V. 

CoreWeave Inc

IREN Limited

Applied Digital Corporation

 are rebounding after a brutal October. Have they bottomed?

Stocktwits Polls

$CDIO how low today   1.40 lets go.   fraud  is imploding.   a 8 min virtual annual shareholder meeting.   ceo is a filthy fraud

Patrick

$CDIO timberrrrrrrrrrr    bankruptcy by halloween or thanksgiving.   CEO keep up that continued success

$CDIO investor relation douche must have left.   now when you call it goes to ceo voicemail.   this company is beyond pathetic

Feed

News

Sentiment

Earnings

Fundamentals

Info

CDIO Cardio Diagnostics Holdings Inc

Fundamentals

Latest CDIO News